Global Information
회사소개 | 문의 | 비교리스트

복막염 : 파이프라인 리뷰

Peritonitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 05월 상품 코드 360906
페이지 정보 영문 45 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


복막염 : 파이프라인 리뷰 Peritonitis - Pipeline Review, H1 2020
발행일 : 2020년 05월 페이지 정보 : 영문 45 Pages

복막염은 복막에 염증이 생긴 것으로 두 종류의 복막염이 있습니다. 자연 세균성 복막염(SBP)은 복강액 감염증에 의한 것입니다. 2차 복막염은 일반적으로 소화관에서부터 퍼진 감염증에 의한 것입니다. 증후로는 복부 팽만, 구토, 설사, 피로, 열과 추운 느낌 등이 있습니다. 치료에는 항생물질을 이용합니다.

복막염(Peritonitis) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 치료제 개발 참여 기업 및 약제 개요, 최신 파이프라인 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

복막염 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

복막염 치료제 개발 참여 기업

  • Adenium Biotech ApS
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Oncodesign SA
  • SynAct Pharma AB

약제 프로파일

복막염 : 휴지중인 프로젝트

복막염 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.08.17

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Peritonitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Peritonitis - Pipeline by Arrevus Inc, H1 2020
  • Peritonitis - Pipeline by Ayuvis Research Inc, H1 2020
  • Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Peritonitis - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
  • Peritonitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H1 2020
  • Peritonitis - Pipeline by Nosopharm SAS, H1 2020
  • Peritonitis - Pipeline by Oncodesign SA, H1 2020
  • Peritonitis - Pipeline by Reponex Pharmaceuticals Aps, H1 2020
  • Peritonitis - Pipeline by SynAct Pharma AB, H1 2020
  • Peritonitis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Peritonitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H1 2020, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Peritonitis - Overview
  • Peritonitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Peritonitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Peritonitis - Companies Involved in Therapeutics Development
  • Arrevus Inc
  • Ayuvis Research Inc
  • GlaxoSmithKline Plc
  • Hunan Sanqing Pharmaceutical Co Ltd
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Nosopharm SAS
  • Oncodesign SA
  • Reponex Pharmaceuticals Aps
  • SynAct Pharma AB
  • Peritonitis - Drug Profiles
  • AP-1189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARV-1502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aspoxicillin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVR-25 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceforanide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • molgramostim - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOSO-502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ODS-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit NLRP3 for Inflammatory Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRT-3025 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peritonitis - Dormant Projects
  • Peritonitis - Product Development Milestones
  • Featured News & Press Releases
  • Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q